印楝提取物(Azadirachta indica Extract) - 在研适应症：牙周炎_专利_临床

概要

基本信息

药物类型

中药

别名

Neem

靶点-

作用方式-

作用机制-

治疗领域

口颌疾病

在研适应症

牙周炎

非在研适应症-

原研机构

Ain Shams University

在研机构

Ain Shams University

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

12

项与印楝提取物相关的临床试验

CTRI/2025/03/081808

/ Not yet recruiting临床3期IIT

Conceptual and applied study of Hrasahetur-Visheshashch Siddhant w.s.r. to Urdhvaga Amlapitta by comparing the efficacy of Nimba (Azadirachta indica A. Juss) and Patola (Trichosanthes dioca Roxb.) Churna. - NIL

开始日期2025-06-01

申办/合作机构-

CTRI/2025/04/084556

/ Not yet recruitingN/AIIT

Plaque Removal Effectiveness Between Different Manual Toothbrushes With Nylon, Neem And Charcoal Infused Bristle Types : A Randomized Control Trial - NIL

开始日期2025-04-30

申办/合作机构-

CTRI/2024/10/075956

/ Not yet recruiting临床2/3期IIT

In vitro evaluation of antifungal activity of homoeopathic medicine Azadirachta indica against pityrosporum ovale and randomised controlled trial in patients with dandruff - NIL

开始日期2024-11-05

申办/合作机构-

100 项与印楝提取物相关的临床结果

登录后查看更多信息

100 项与印楝提取物相关的转化医学

登录后查看更多信息

100 项与印楝提取物相关的专利（医药）

登录后查看更多信息

252

项与印楝提取物相关的文献（医药）

2025-04-01·Molecular Immunology

Neem leaf extract alleviates LPS/D-GalN induced acute hepatitis in mice through its anti-inflammatory effects and activation of autophagy

Article

作者: Jin, Meiyu ; Yu, Hao ; Zhai, Yaxin ; Zhang, Yibo ; Cheng, Jiaqi ; Mengfan, L V ; Feng, Haihua

Acute hepatitis, characterized by rapid onset and high mortality, can result from infections, toxins, and other factors. However, current treatment options have significant side effects, necessitating further research into alternative therapies. This study investigated the extraction method of neem extract and found that its ethanolic extract effectively reduced mortality and decreased ALT and AST levels in mice serum, improving liver pathology. HPLC analysis identified azadirachtin and nimbolide in the extract. It also downregulated NF-κB, NLRP3, and p62 levels, while upregulating Lc3B and Atg5 levels. Experiments in Atg5 knockout mice showed that the absence of Atg5 weakened the extract's efficacy in reducing liver damage and inflammation and affected the extent of NLRP3 protein downregulation. However, it did not affect the extract's ability to reduce NF-κB. Overall, the ethanolic extract of neem leaves primarily modulates the inflammatory response through the NF-κB signaling pathway. The extract's efficacy in reducing NLRP3 is associated with autophagy. These discoveries offer a new theoretical basis for the role of neem in treating acute hepatitis.

2025-02-01·Heliyon

Screening of aqueous plant extracts for immunomodulatory effects on immune cells and cytokine production: In vitro and in vivo analyses

Article

作者: Lomthaisong, Komsorn ; Areemit, Jringjai ; Dobutr, Theerawat ; Kulchat, Sirinan ; Daduang, Jureerut ; Patramanon, Rina ; Daduang, Sakda ; Jangpromma, Nisachon

This study investigates the immunomodulatory effects of various aqueous plant extracts on immune cells and cytokine production. In vitro, several extracts, including holy basil (Ocimum sanctum), patawali (Tinospora crispa), and Indian borage (Plectranthus amboinicus L.), significantly increased CD3⁺ T-cell populations, while soap pod (Acacia concinna), garlic (Allium sativum L.), and neem (Azadirachta indica) also boosted CD45RA⁺ B-cells. In vivo, the extracts had subtle effects on spleen morphology and Peyer's Patches, with milk bush (Euphorbia tirucalli L.) and Indian borage enhancing T-cell responses, while soap pod stimulated B-cells. Additionally, we observed that Neem and milk bush significantly suppressed B-cell populations. Furthermore, cytokine analysis showed that garlic and patawali reduced IL-2, while soap pod, holy basil, and patawali increased TNF-alpha levels. Soap pod also elevated IL-10 and IL-17A, indicating both anti-inflammatory and pro-inflammatory signaling, while patawali induced an increase in IL-4. In conclusion, Thai medicinal plants show strong potential as both immunostimulants and immunosuppressants. They can enhance lymphocyte proliferation, particularly in T-cells, and modulate B-cell populations. Their aqueous extracts play a key role in regulating Th1, Th2, and Th17 cytokine production. Thus, these plants could serve as natural agents and alternative medicines for boosting or modulating immune function.

2024-12-18·Cureus

Uncovering the Role of Indian Medicinal Botanicals in COVID-19 Prevention and Management: A Review

Review

作者: S, Vinayaka K ; Ammu Joseph, Renju ; Shrivastava, Ruchita ; Karra, Theresa ; Vasudeo Damodar, Sarwade ; Mishra, Jyotsana ; Rao, D Meena S ; Gajendra Bagal, Jalindarnath

Indian traditional medicine, based on Ayurveda and Siddha, has become one of the global searches for complementary approaches to conventional interventions during the COVID-19 pandemic. This review presents the antiviral, immune-boosting, and anti-inflammatory properties of some medicinal key plants such as Tulsi (Ocimum sanctum), Neem (Azadirachta indica), Ashwagandha (Withania somnifera), Amla (Emblica officinalis), and Giloy (Tinospora cordifolia). Tulsi appears to inhibit viral replication, Neem increases immune cell synthesis, while Ashwagandha regulates inflammation and stress responses. Vitamin C-rich Amla increases immune defense while also providing protection against oxidative stress and Giloy modulates immune response and its activity, acting as an overall resilience against infection. However, the clinical integration of these plants into mainstream healthcare is hindered by the absence of robust clinical trials, standardization of phytochemicals, and the absence of global standard protocols. In order to establish safety and efficacy, substantial research is needed, including large-scale randomized clinical trials and sophisticated bioinformatics techniques. Indian medicinal plants provide innovative, sustainable, and holistic solutions to global health crises, such as the COVID-19 pandemic, by bridging traditional knowledge with modern scientific frameworks.

100 项与印楝提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
牙周炎	临床2期	埃及	Ain Shams University	2021-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01898091 (OM, CTgov)	临床2期	肿瘤 \| 放射性口腔黏膜炎	50	Placebo Mouthrinse+Neem Mouthrinse (Neem Mouthrinse)	壓廠顧繭窪鏇構夢遞壓(鏇壓襯壓夢獵憲餘餘願) = 醖憲構艱範鑰膚願衊窪鏇鬱鹽蓋淵夢餘繭糧鏇 (築積鏇鏇網簾願鑰獵艱, 鹽艱觸襯夢淵襯顧積鑰 ~ 鑰艱窪壓醖鏇鑰憲範蓋) 更多	-	2017-03-06
				Placebo Mouthrinse (Placebo Mouthrinse)	壓廠顧繭窪鏇構夢遞壓(鏇壓襯壓夢獵憲餘餘願) = 襯築顧簾廠膚糧廠醖齋鏇鬱鹽蓋淵夢餘繭糧鏇 (築積鏇鏇網簾願鑰獵艱, 構鑰夢夢鏇遞壓壓願顧 ~ 網蓋壓膚構獵簾艱範窪) 更多